Spectral AI, Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 29, 2024. This is an annual report, not a standalone fourth-quarter results report; quarterly figures are not clearly provided in the filing text.
Business context
Spectral AI is a pre-commercial-stage medical diagnostics company developing DeepView, a multispectral imaging device and AI software intended to predict burn and diabetic foot ulcer (DFU) wound-healing potential. The company reported no product sales; substantially all revenue came from government-funded research and development contracts, predominantly BARDA. It completed a SPAC business combination on September 11, 2023, and began Nasdaq trading as MDAI (common stock) and MDAIW (warrants).
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Research and development revenue | $18.1 million | $25.4 million |
| Gross profit / gross margin | $7.9 million / 43.6% | $10.8 million / 42.7% |
| Operating loss | $13.0 million | $2.6 million |
| Net loss | $20.9 million | $2.9 million |
| Adjusted EBITDA, non-GAAP | $(11.7) million | $(1.5) million |
| Cash used in operating activities | $13.2 million | $1.2 million |
Revenue fell 28.8%, primarily reflecting reduced activity as the BARDA Burn II contract neared completion; the new BARDA contract began in the fourth quarter. BARDA generated $17.0 million, or about 94% of revenue, in 2023. General and administrative expense rose 54.7% to $20.9 million, including higher personnel and non-revenue-generating R&D costs. Net loss included $8.3 million of transaction costs, mainly related to the business combination.
At December 31, 2023, cash was $4.8 million, down from $14.2 million a year earlier; current assets were $9.9 million and current liabilities $12.4 million. The company reported $0.4 million of notes payable, no long-term debt, and an accumulated deficit of $32.8 million. Operating cash outflow was partly offset by $3.8 million of financing cash inflow, including equity-raise proceeds and cash received in the business combination. The filing reports no off-balance-sheet arrangements.
Material changes and unusual items
- The September 2023 BARDA Project BioShield contract provides up to approximately $150 million: an initial $54.9 million award plus approximately $95.1 million in optional funding. Options and milestone payments are not assured.
- Business-combination accounting was a reverse recapitalization. The company recorded $8.3 million in transaction costs in 2023, including noncash stock issued for some costs.
- Warrant liabilities increased to $1.8 million at year-end from $0.1 million; changes in their fair value are recorded in earnings.
- After year-end, the company reported using the B. Riley equity facility to sell shares for $2.7 million of proceeds through March 25, 2024, with $0.7 million of associated offering costs. It also entered a Yorkville arrangement that includes a share-purchase facility of up to $30 million and convertible-note advances of up to $12.5 million; the first $5 million advance was funded March 20, 2024. These financings may cause dilution and have conditions and limits.
Outlook, risks, and contingencies
The company says existing cash, BARDA and MTEC funding, and available financing facilities are expected to support operations for at least 12 months from the financial statements’ release date. This is management’s estimate, depends on assumptions and contingent funding, and does not establish profitability or eliminate the possibility of further capital needs.
DeepView burn performance reported in ongoing studies was 92% accuracy for adults and 88% for pediatric patients; reported DFU accuracy was 86%. These are company-reported clinical results, not a guarantee of future performance or regulatory authorization. UKCA marking for the full DeepView burn system was completed in March 2024, with UK burn sales targeted for the second half of 2024. The company targets U.S. DFU authorization in 2025 and U.S. burn submission around 2025; the filing gives differing timing descriptions for the burn submission. Regulatory review, study completion, reimbursement, commercial adoption, and launch dates remain uncertain.
Key risks include heavy reliance on BARDA and other government contracts, no commercial sales, ongoing losses and cash consumption, possible need for additional capital, clinical or regulatory delays, and the need to build sales and distribution capabilities. Further risks include reimbursement and pricing uncertainty, reliance on contract manufacturers and suppliers, product liability, privacy and cybersecurity exposure, evolving AI regulation, and potential dilution from equity facilities, warrants, and stock awards. The company disclosed a material threatened claim it believes is without merit; it reported no material pending legal proceedings.
Management concluded that internal control over financial reporting was ineffective at year-end and disclosure controls were not effective, citing three material weaknesses involving communication about complex transactions, expense/accrual and unbilled-revenue cutoff, and financial close and account-reconciliation controls. Remediation is ongoing. The auditor gave an unqualified opinion on the financial statements but did not opine on internal-control effectiveness.
Important facts for investors to verify
- BARDA contract milestones, reimbursement, and exercise of optional funding; confirm how much funding is committed, earned, and collected.
- Available liquidity and cash runway, including the conditions, costs, repayment terms, share limits, and dilution associated with B. Riley and Yorkville financing.
- Clinical-study progress and whether reported accuracy results are confirmed in pivotal studies and accepted by regulators.
- Regulatory status and launch timing by indication and geography, including the filing’s differing projected timing for the U.S. burn submission.
- Progress remediating the disclosed material weaknesses and whether controls operate effectively over a sufficient period.